2023
Prevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil
Pacheco S, Schinoni M, Stocker A, Paraná R, Reis M, Silva L. Prevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i3.3473.Peer-Reviewed Original ResearchGenotypic resistance mutationsResistance mutationsHepatitis BChronic hepatitis BFirst-line treatmentVaccine escape mutationsHepatitis B virusChronic HBVAntiviral treatmentLine treatmentLiver diseaseTherapeutic managementB virusEscape mutationsGenotypic resistanceReference centerPatientsGenetic mutationsEntecavirHBVTenofovirTreatmentNortheast of BrazilPresent studyNucleotide analogues
2014
Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis
Lima I, Oliveira R, Cabral M, Atta A, Marchi S, Reis E, Reis M, Barbosa L, Santiago M. Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis. Rheumatology International 2014, 34: 1231-1234. PMID: 24719228, DOI: 10.1007/s00296-014-3009-z.Peer-Reviewed Original ResearchConceptsAnti-neutrophil cytoplasmic antibodiesAnti-PR3 antibodiesIndirect immunofluorescencePresence of ANCAPrevalence of ANCAInfectious diseasesComponents of neutrophilsGroup of patientsAnti-MPO antibodiesSera of patientsChest X-rayAnti-PR3Cytoplasmic antibodiesVasculitic syndromesTB patientsPulmonary tuberculosisAutoimmune disordersPresent studyClinical similaritiesSuch antibodiesPatientsELISA kitTuberculosisAntibodiesAutoantibodies